Compare STWD & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STWD | PTCT |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 6.1B |
| IPO Year | 2009 | 2013 |
| Metric | STWD | PTCT |
|---|---|---|
| Price | $18.20 | $72.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 18 |
| Target Price | $20.63 | ★ $76.28 |
| AVG Volume (30 Days) | ★ 3.6M | 1.2M |
| Earning Date | 02-25-2026 | 02-19-2026 |
| Dividend Yield | ★ 10.68% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.04 | ★ 8.94 |
| Revenue | $490,651,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $366.38 | $132.16 |
| Revenue Next Year | $12.15 | N/A |
| P/E Ratio | $17.27 | ★ $8.30 |
| Revenue Growth | 12.42 | ★ 97.54 |
| 52 Week Low | $16.59 | $35.95 |
| 52 Week High | $21.05 | $87.50 |
| Indicator | STWD | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 39.99 |
| Support Level | $17.88 | $71.35 |
| Resistance Level | $18.49 | $76.99 |
| Average True Range (ATR) | 0.29 | 2.89 |
| MACD | -0.00 | -0.25 |
| Stochastic Oscillator | 60.11 | 12.52 |
Starwood Property Trust Inc is an American real estate investment trust principally engaged in originating, acquiring, and managing commercial mortgage loans and commercial mortgage-backed securities in the U.S. and Europe. The company organizes its activities into Commercial and Residential Lending Segment, Infrastructure Lending Segment, Property Segment, and Investing & Servicing Segment. The company generates the majority of its revenue from the Commercial and Residential Lending Segment, which is engaged in originating, acquiring, financing, and managing commercial first mortgages, and non-agency residential mortgages.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.